002424.SZ
ST百灵
SZSE · Healthcare · C 制造业 · CN
CNY 4.55
+0.66%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
35.7x
Market Cap
CNY 6.36B
MomentumView details →
1D Return
+0.66%
YTD Return
+5.52%
RSI (14)
51.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
35.7x
Market Cap
CNY 6.36B
RSI (14)
51.2
MomentumView details →
1D Return
+0.66%
YTD Return
+5.52%
Similar companies
Latest newsMore news →
ST Bailing's wholly-owned subsidiary BaiLing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration to conduct clinical trials for the inhaled drug BD77 for chronic obstructive pulmonary disease.4d agoST Bailing's wholly-owned subsidiary received pre-approval from the Macao SAR Drug Administration (ISAF) to conduct a Phase III clinical trial for its traditional Chinese medicine product Tangningtongluo Tablet, the first such pre-approval for a new TCM drug in Macao.8d ago